Skip to content
10-Q

Quarterly Report

AMAG PHARMACEUTICALS, INC.

0000792977-20-000043

← back to feed
Filed
May 11, 2020 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2020 · May 6, 2020 34.27M sh
Stock Repurchased Q1 2020 · Mar 31, 2020 $0
Stock Repurchased Q1 2020 · Mar 31, 2019 $13.73M
Capex Q1 2020 · Mar 31, 2020 $68K
Capex Q1 2020 · Mar 31, 2019 $1.79M
Operating Cash Flow Q1 2020 · Mar 31, 2020 −$46.61M
Operating Cash Flow Q1 2020 · Mar 31, 2019 −$89.91M
Long Term Debt Q1 2020 · Mar 31, 2020 $281.04M
Long Term Debt Q1 2020 · Dec 31, 2019 $277.03M
Short Term Debt Q1 2020 · Mar 31, 2020 $0
Short Term Debt Q1 2020 · Dec 31, 2019 $0
Cash And Equivalents Q1 2020 · Mar 31, 2020 $54.46M
Cash And Equivalents Q1 2020 · Dec 31, 2019 $113.01M
Stockholders Equity Q1 2020 · Mar 31, 2020 $263.74M
Stockholders Equity Q1 2020 · Dec 31, 2019 $286.12M
Stockholders Equity Q1 2020 · Mar 31, 2019 $614.72M
Stockholders Equity Q1 2020 · Dec 31, 2018 $746.66M
Current Liabilities Q1 2020 · Mar 31, 2020 $188.25M
Current Liabilities Q1 2020 · Dec 31, 2019 $208.19M
Total Liabilities Q1 2020 · Mar 31, 2020 $489.84M
Total Liabilities Q1 2020 · Dec 31, 2019 $505.11M
Current Assets Q1 2020 · Mar 31, 2020 $290.64M
Current Assets Q1 2020 · Dec 31, 2019 $316.57M
Total Assets Q1 2020 · Mar 31, 2020 $753.58M
Total Assets Q1 2020 · Dec 31, 2019 $791.23M
Sga Expense Q1 2020 · Mar 31, 2020 $52.7M
Sga Expense Q1 2020 · Mar 31, 2019 $74.68M
Net Income Q1 2020 · Mar 31, 2020 −$24.49M
Net Income Q1 2020 · Mar 31, 2019 −$122.08M
Operating Income Q1 2020 · Mar 31, 2020 −$19.58M
Operating Income Q1 2020 · Mar 31, 2019 −$117.7M
Cost Of Revenue Q1 2020 · Mar 31, 2020 $24.36M
Cost Of Revenue Q1 2020 · Mar 31, 2019 $18.48M
Revenue Q1 2020 · Mar 31, 2020 $68.66M
Revenue Q1 2020 · Mar 31, 2019 $75.8M